专利检索_ .含-CHO基专利检索_ .含-CHO基专利检索查询

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
161	Benzamide derivative	JP13207678	1978-10-25	JPS5470275A	1979-06-05	ROJIYAA EDOWAADO FUOODO; FUIRITSUPU NOURUZU; EDOWAADO RUNTO; SUCHIYUAATO MARUKOMU MAASHIYAR; ANSONII JIYON HENRII SAMAAZU

162	Benzamide derivatives	JP13299377	1977-11-04	JPS5359669A	1978-05-29	ROJIYAA EDOWAADO FUOODO; FUIRITSUPU NOURUZU; EDOWAADO RUNTO; SUCHIYUAATO MARUKOMU MAASHIYAR; ANSONII JIYON HENTEII SAMAAZU

163	Production of penicillin ester	JP10216376	1976-08-25	JPS5253888A	1977-04-30	HARII FUERESU; JIYON PIITAA KUREITON

164	Preparation and use of novel 22hydroxynaphthalinee 11aldehyde	JP8928476	1976-07-28	JPS5217454A	1977-02-09	TEODOORU PAAPENFUUSU; HAINRITSUHI FUORUKU

165	Hatsushokuseishikiryokagobutsu	JP13674475	1975-11-13	JPS5174021A	1976-06-26	DERETSUKU JEE ORUSOPU

166	Shinkinahokozoku 00 hidorokishiarudehidokagobutsunoseiho	JP8969875	1975-07-24	JPS5148642A	1976-04-26	TEODOORU PAAPENFUUSU; HERUMUUTO TOREESUTERU

167	COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN	EP14768317	2014-03-10	EP2970308A4	2016-08-10	METCALF BRIAN W; LI ZHE; XU QING; GWALTNEY STEPHEN L II; HARRIS JASON R; YEE CALVIN W
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
168	IRE-1A INHIBITORS	EP08770492.0	2008-06-09	EP2155643B1	2016-08-10	PATTERSON, John, Bruce; LONERGAN, David, Gregory; FLYNN, Gary A.; ZHENG, Qingping; PALLAI, Peter V.
Methods of treating disorders associated with unfolded protein response and methods of inhibiting IRE-1± activity are provided.
169	IRE-1A Inhibitors	EP12171202.0	2008-06-09	EP2532643A1	2012-12-12	Patterson, John Bruce; Lonergan, David Gregory; Flynn, Gary A.; Zeng, Qingping; Pallai, Peter V.
Methods of treating disorders associated with unfolded protein response and methods of inhibiting IRE-1α activity are provided.
170	IRE-1A INHIBITORS	EP08770492.0	2008-06-09	EP2155643A1	2010-02-24	PATTERSON, John, Bruce; LONERGAN, David, Gregory; FLYNN, Gary A.; ZHENG, Qingping; PALLAI, Peter V.
Methods of treating disorders associated with unfolded protein response and methods of inhibiting IRE-1± activity are provided.
171	BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS	EP05799391.7	2005-10-26	EP1806332A1	2007-07-11	TAMAKI, Kazuhiko c/o Sanky Company Limited; YAMAGUCHI, Takahiro c/o Sankyo Company Limited; ODA, Kozo c/o Sankyo Company Limited; TERASAKA, Naoki c/o Sankyo Company Limited; NAKAI, Daisuke c/o Sankyo Company Limited; NAKADAI, Masakazu c/o Sankyo Company Limited
A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R¹: -COR⁹ (wherein R⁹: alkyl, optionally substituted alkoxy or optionally substituted amino); R²: H, OH, alkoxy, optionally substituted amino, etc.; R³: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R⁴ and R⁵: H, optionally substituted alkyl, halogeno, etc.; R⁶ and R⁷: H, alkyl; R⁸: -X²R¹⁰ [wherein R¹⁰: -COR¹¹ (wherein R¹¹ : OH, optionally substituted alkoxy, optionally substituted amino, etc.), -SO₂R¹² (wherein R¹²: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X²: single bond, optionally substituted alkylene, etc.]; X¹: -NH-, -O-, -S-, etc.; Y¹: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y²: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.
172	LIGANDS OF ADENINE NUCLEOTIDE TRANSLOCASE (ANT) AND COMPOSITIONS AND METHODS RELATED THERETO	EP03814376.4	2003-12-19	EP1581472A2	2005-10-05	GHOSH, Soumitra, S.; PEI, Yazhong; TANG, Xiao-Qing; LIRAS, Spiros, J.; AHLIJANIAN, Michael, K.
Compounds which have utility in the treatment of conditions associated with altered mitochondrial function. The compounds having structure (I), including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.
173	METHOD OF MODIFYING COMPONENTS PRESENT IN CASHEW NUT SHELL LIQUID	EP99963628.5	1999-11-25	EP1131277B1	2005-07-13	KHAN, Mohammed, Lokman; TOMKINSON, Jeremy; SALISBURY, Richard, James
The invention provides a process for modifying CNSL comprising subjecting the CNSL to ozonolysis to form ozonolysis reaction products followed by reduction of the ozonolysis reaction products to give a mixture of phenolic components and aldehydes. In a preferred embodiment, the invention provides a process for modifying CNSL which comprises the steps of first reacting CNSL with ozone to form a mixture containing ozonolysis reaction products, and secondly treating the mixture under reducing conditions to form a further mixture containing phenolic components with an eight carbon chain having a terminal CHO group and alkyl components of varying lengths with either one or two terminal CHO groups. The resulting CNSL aldehydes can be used to form adhesives for use in the manufacture of composites such as wood particle board.
174	NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS	EP01918784.8	2001-03-16	EP1265840A2	2002-12-18	JOHNSON, David
This invention relates to novel aldehyde containing compounds and their uses as adjuvants and immunoeffectors.
175	METHOD OF MODIFYING COMPONENTS PRESENT IN CASHEW NUT SHELL LIQUID	EP99963628.5	1999-11-25	EP1131277A1	2001-09-12	KHAN, Mohammed, Lokman; TOMKINSON, Jeremy; SALISBURY, Richard, James
The invention provides a process for modifying CNSL comprising subjecting the CNSL to ozonolysis to form ozonolysis reaction products followed by reduction of the ozonolysis reaction products to give a mixture of phenolic components and aldehydes. In a preferred embodiment, the invention provides a process for modifying CNSL which comprises the steps of first reacting CNSL with ozone to form a mixture containing ozonolysis reaction products, and secondly treating the mixture under reducing conditions to form a further mixture containing phenolic components with an eight carbon chain having a terminal CHO group and alkyl components of varying lengths with either one or two terminal CHO groups. The resulting CNSL aldehydes can be used to form adhesives for use in the manufacture of composites such as wood particle board.
176	LTB4 Synthesis inhibitors	EP90124571.2	1990-12-18	EP0435134B1	1995-06-21	Djuric, Stevan Wakefield; Miyashiro, Julie Marion; Haack, Richard Arthur

177	LTB4 Synthesis inhibitors	EP90124571.2	1990-12-18	EP0435134A3	1992-05-13	Djuric, Stevan Wakefield; Miyashiro, Julie Marion; Haack, Richard Arthur
This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof wherein X is oxygen, sulfur, -CH = CH-or -CH = N-; wherein R₁ is alkyl, alkenyl or alkynyl of about 1 to 20 carbon atoms; wherein R is -C0₂R², tetrazole, methylsulfonamide or benzenesulfonamide, wherein R² is hydrogen, alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation and R³ is hydroxyl or halogen, having utility as LTB4 synthesis inhibitors.
178	Verfahren zur Herstellung von 4,4'-Stilbendialdehyden	EP86810587.5	1986-12-15	EP0229593B1	1991-10-16	Reinehr, Dieter, Dr.; Steiner, Heinz

179	LTB4 Synthesis inhibitors	EP90124571.2	1990-12-18	EP0435134A2	1991-07-03	Djuric, Stevan Wakefield; Miyashiro, Julie Marion; Haack, Richard Arthur
This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof wherein X is oxygen, sulfur, -CH = CH-or -CH = N-; wherein R₁ is alkyl, alkenyl or alkynyl of about 1 to 20 carbon atoms; wherein R is -C0₂R², tetrazole, methylsulfonamide or benzenesulfonamide, wherein R² is hydrogen, alkyl of 1 to 6 carbon atoms or a pharmaceutically acceptable cation and R³ is hydroxyl or halogen, having utility as LTB4 synthesis inhibitors.
180	Verfahren zur Herstellung von 4,4'-Stilbendialdehyden	EP86810587.5	1986-12-15	EP0229593A1	1987-07-22	Reinehr, Dieter, Dr.; Steiner, Heinz
Herstellung von 4,4ʹ-Stilbendialdehyden aus den entsprechenden Säurechloriden in Gegenwart von Edelmetallkatalysatoren.

3 4 5 6 7 8 9 10 11 12

该功能需要专业版企业版VIP权限，您可以：